InnoCare Pharma stock drops as revenue surges 88%, Eli Lilly deal expands global reach

InnoCare Pharma's stock dropped as the company reported revenue surging 88%, with an expanded Eli Lilly deal extending its global reach.

Detected & updated continuously · Source: Nebula